التفاصيل البيبلوغرافية
| العنوان: |
Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date. |
| المؤلفون: |
Hill, Lucas, Smith, Shawn R, Karris, Maile Young |
| المصدر: |
HIV/AIDS - Research & Palliative Care; Oct2018, Vol. 10, p203-213, 11p |
| مصطلحات موضوعية: |
HIV infections, PHARMACOLOGY, ANTIRETROVIRAL agents, PHARMACOKINETICS, DRUG development |
| مستخلص: |
Modern pharmacologic management of people living with HIV involves the use of fixed dose combinations of antiretrovirals that are simple to take, well tolerated, and highly effective. Specific recent pharmacologic advancements include 1) the second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) that consistently show less side effects, high tolerability, minimal drug interactions, and rapid rates of HIV viral load decline and 2) tenofovir alafenamide, a prodrug of tenofovir that concentrates in lymphoid tissue and minimizes off target effects. Bictegravir/emtricitabine/tenofovir alafenamide or B/F/TAF is a recently approved fixed dose combination that incorporates these new advancements in the management of HIV. This review focuses on the data supporting the use of B/F/TAF, reviews clinically relevant findings, and highlights the unanswered questions that may limit its clinical utility. [ABSTRACT FROM AUTHOR] |
|
Copyright of HIV/AIDS - Research & Palliative Care is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder